Eficacia y seguridad de distintas cepas de BCG en el tratamiento del tumor vesical en práctica clínica habitual

Unda, Miguel; Cozar-Olmos, J.M.; Miñana-López, B.; Camarero-Jimenez, J.; Brugarolas-Rossello, X.; Zubiaur-Libano, C.; Ribal-Caparrós, M.J.; Suarez-Charneco, A.J.; Rodríguez-Tesedo, V.; Chantada-Abal, Venancio; Ruiz-de-Leon, C.; Carrillo-George, Carlos; Carballido-Rodríguez, Joaquín; Villacampa, Felipe

doi:10.1016/j.acuro.2017.10.003

Cited by 26 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The substrains differ especially in the composition and the number of certain components of their cell wall, which applies especially to mycolic acids, phthiocerol dimycocerosates (PDIM), and phenolic glycolipids (PGLs)—lipids that play a particular role in microbe–host interactions [ 130 ]. Although the majority of studies indicate the lack of advantage of any of the BCG substrains over the others in terms of effectiveness in the therapy of nonmuscle-invasive bladder cancer (NMIBC) [ 131 , 132 , 133 ], some reports indicate such differences. Comparing the effectiveness of the two commonly used BCG strains in the treatment of NMIBC Connaught and Tice, a significant difference in the length of the relapse-free period was observed in favor of the former, indicating a difference in the immunogenicity of the two strains [ 134 ].…”

Section: Mycobacteria As Therapeutic Agentsmentioning

confidence: 99%

Dual Nature of Relationship between Mycobacteria and Cancer

Fol

Koziński²,

Kulesza

et al. 2021

IJMS

View full text Add to dashboard Cite

Although the therapeutic effect of mycobacteria as antitumor agents has been known for decades, recent epidemiological and experimental studies have revealed that mycobacterium-related chronic inflammation may be a possible mechanism of cancer pathogenesis. Mycobacterium tuberculosis and non-tuberculous Mycobacterium avium complex infections have been implicated as potentially contributing to the etiology of lung cancer, whereas Mycobacterium ulcerans has been correlated with skin carcinogenesis. The risk of tumor development with chronic mycobacterial infections is thought to be a result of many host effector mechanisms acting at different stages of oncogenesis. In this paper, we focus on the nature of the relationship between mycobacteria and cancer, describing the clinical significance of mycobacteria-based cancer therapy as well as epidemiological evidence on the contribution of chronic mycobacterial infections to the increased lung cancer risk.

show abstract

Section: Mycobacteria As Therapeutic Agentsmentioning

confidence: 99%

Dual Nature of Relationship between Mycobacteria and Cancer

Fol

Koziński²,

Kulesza

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Although the gold standard management for NMIBC is complete removal of all papillary lesions via transurethral resection (TUR), there is a high rate of recurrence after the initial surgery. For all high grade and some low grade NMIBC, intravesical immunotherapy of bacillus Calmette-Guérin (BCG) is the one recommended in all the guidelines [2]. The meta-analyses of randomized trials have shown that intravesical maintenance BCG after TUR reduced the recurrence rates significantly [3], and BCG significantly reduces the risk of progression to muscle invasive disease after TUR in patients who receive maintenance BCG [4].…”

Section: Introductionmentioning

confidence: 99%

Clinical Spectrum of Complications Induced by Intravesical Immunotherapy of Bacillus Calmette-Guérin for Bladder Cancer

Liu

Huang

et al. 2019

Journal of Oncology

View full text Add to dashboard Cite

Because of its proven efficacy, intravesical Bacillus Calmette-Guérin (BCG) immunotherapy is an important treatment for nonmuscle invasive bladder cancer at high risk of recurrence or progression. However, approximately 8% of patients have to stop BCG instillation as a result of its complications. Complications induced by BCG therapy can have a variety of clinical manifestations. These adverse reactions may occur in conjunction with BCG instillation or may not develop until months or years after BCG cessation. An essential step in the management complications arising from BCG is early establishment of diagnosis, particularly for distant, disseminated, and obscure infections. Therefore we reviewed the literature on the potential complications after intravesical BCG immunotherapy for bladder cancer and provide an overview on the incidence, diagnosis, and treatment modality of genitourinary and systemic BCG-induced complications.

show abstract

“…In the same report, Rentsch et al [14] treated mice with the same BCG substrains and showed, in the animal model, that BCG Connaught induced a stronger Th1 response, greater priming of BCG-specific CD8 + T cells, and more robust T-cell recruitment to the bladder than BCG TICE. Other retrospective studies in BCG-treated bladder cancer patients conclude, however, that there is not much difference between BCG substrains in the treatment of bladder cancer on progression-free survival or diseasespecific survival [15].…”

Section: Introductionmentioning

confidence: 91%

Natural killer activation for bladder cancer elimination can be achievedin vitroby heat-killed BCG

Esteso

Aguiló

Julián

et al. 2020

Preprint

View full text Add to dashboard Cite

Immunotherapy, via intravesical instillations of Bacillus Calmette-Guérin (BCG) is the therapy of choice for patients with high risk non-muscle invasive bladder cancer. The subsequent recruitment of lymphocytes and myeloid cells, as well as the release of cytokines and chemokines, induces a local immune response that contributes to eliminate these tumours. The history of BCG development resulted in a large number of genetically diverse BCG substrains which could stimulate the immune system in different ways. Here, while investigating the capacity of different BCG substrains to promote the activation of NK cells, we confirmed that all the evaluated substrains could activate a cytotoxic CD56 bright NK cell population which efficiently degranulated against bladder cancer cells; Tice, Connaught and Moreau were the substrains having a stronger effect. Dead mycobacteria also stimulated PBMC cultures and we demonstrate that subcellular fractions of BCG-Tice could contribute to the induction of this NK cell response. Lipids from BCG-Tice, but not from Mycobacterium bovis, stimulated NK cell activation and degranulation, however the aqueous fraction of either bacteria did not activate lymphocytes.Delipidated BCG-Tice activated effector cells (CD3 + CD56 + and NK). These data suggest that different immune subpopulations could be stimulated using different fractions of mycobacteria for cancer elimination.

show abstract

Eficacia y seguridad de distintas cepas de BCG en el tratamiento del tumor vesical en práctica clínica habitual

Cited by 26 publications

References 21 publications

Dual Nature of Relationship between Mycobacteria and Cancer

Dual Nature of Relationship between Mycobacteria and Cancer

Clinical Spectrum of Complications Induced by Intravesical Immunotherapy of Bacillus Calmette-Guérin for Bladder Cancer

Natural killer activation for bladder cancer elimination can be achievedin vitroby heat-killed BCG

Contact Info

Product

Resources

About